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Abstract
Objective: Identification of clinical features suggestive of pulmonary blastoma (PB) through a retrospective comparison with cases of
non-small cell lung cancer (NSCLC) operated during the same period. Methods: Between 1977 and 1999, five patients were operated for PB
at Geneva University Hospital (four women and one man, aged 32–46 years – mean 36.8) versus 1913 consecutive patients (1558 men and
355 women, mean age 61.2) for primary NSCLC. In the PB subgroup (0.3%), the pulmonary tumor was single, located in an upper lobe in all
but one instance, and measured between 5 and 13 cm (mean 9.6), whereas in the total NSCLC group, 27% of patients had tumors,3 cm (T1),
evenly distributed in both lungs. All but one PB patients were symptomatic, compared to 45% in the NSCLC group. Results: The five
patients with PB underwent curative pulmonary excisions (lobectomy in three and pneumonectomy in two) with mediastinal lymph node
sampling. Pathological examination revealed extensive tumor necrosis in four, and N2 lymph node metastases in four (in the total NSCLC
group, N2 disease was diagnosed in 21%). Postoperatively, three PB patients received radio- and/or chemotherapy. Four patients died
between six and 30 months after the operation (mean 15), whereas 5-year survival in the NSCLC group was 32%, with a median survival of
3.7 years; the fifth patient is alive 28 months later, without any sign of recurrence. Conclusions: Compared to operated NSCLC, PB are rare,
large, and symptomatic tumors; they affect younger patients and carry a worse prognosis.q 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Dismal outlooks in five young cases of pulmonary blas-
toma (PB) operated in Geneva have prompted us to see
whether such a perspective was regularly as grim in other
reported cases of PB, and in what respects PB differed from
the bulk of non-small cell lung cancers (NSCLC). In order
to hasten diagnosis in PB (and hopefully treatment as well),
attention was focused on readily available date, essentially
clinical and radiological. The following features were
compared in both groups of tumors: age, gender, presence
of symptoms, tumor size, mediastinal lymph node involve-
ment, treatment, and survival. Should some of these features
be relied upon to hasten surgery in a rare condition, but
treacherous enough to occasionally mimic other benign
conditions?
2. Methods
Between January 1977 and December 1999, 1913 conse-
cutive patients (1558 men and 355 women, aged between 27
and 83 – mean 61.2) were operated on at the Unit of Thor-
acic Surgery of Geneva University Hospital for primary
NSCLC (Table 1). Five other patients suffered from PB;
there were four women and one man, aged between 32
and 46 years (mean 37). In the latter subgroup, the pulmon-
ary tumor was single, located in an upper lobe in all but one
instance, and measured between 5 and 13 cm (mean 9.6)
(Fig. 1), whereas in the whole group, 27% of patients had
tumors ,3 cm (T1), evenly distributed between upper and
lower lobes.
In the blastoma group, four were heavy smokers (mean 15
pack-years); their personal histories were non-contributive,
except for a 34-year old man who suffered from von Reck-
linghausen’s disease, and a 46-year old woman who was
operated on 2 years earlier for an anal squamous carcinoma
(without signs of recurrence at the time of PB). The latter
was the only asymptomatic patient: the four others
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complained of chest pain, cough, fatigue, and/or weight
loss.
3. Results
The five patients with PB all underwent pulmonary exci-
sions which were considered macroscopically curative at
the time of surgery (a lobectomy in three and a pneumo-
nectomy in two, one with a partial diaphragm resection).
Mediastinal lymph nodes were sampled in all cases and
removed when enlarged.
Pathological examination revealed extensive tumor
necrosis (due to their rapid growth) in four patients, and
N2 lymph node metastases in four (in the whole NSCLC
group, N2 disease was diagnosed in 21% – Table 2). Post-
operatively, three patients received radio- and/or
chemotherapy.
Four patients died between 6 and 30 months after the
operation (mean 15), whereas 5-year survival in the
NSCLC group was 32%, with a median survival of 3.7
years. The fifth patient mentioned previously was treated
6 weeks postoperatively with four courses of a chemother-
apy similar to that used in case of germ-cell tumors which
included cisplatin, 20 mg/m2, VP-16, 100 mg/m2, uromi-
texan, 240 mg/m2, and ifosfamide, 1200 mg/m2, daily
(except for uromitexan given on day 1 only) for 4 days at
4-week intervals; radiotherapy was administered 2 months
after chemotherapy (i.e. 5 months postoperatively) to a total
of 64 Gy in 32 fractions over 7 weeks, covering the areas of
the tumor bed, mediastinum, intermediate bronchus, and top
of the middle lobe. At last follow-up, 33 months postopera-
tively, she is clinically and radiologically free of disease.
4. Discussion
Pulmonary blastomas are characterized by a dual or
biphasic immature cellular component, i.e. epithelial and
mesenchymal, both malignant, which mimics that of fetal
lung [1]. They are extremely rare malignant primary lung
cancers, since some 200 cases only have been reported since
Barrett and Barnard’s original description in 1945 [2]. In
surgical series which usually exclude small cell lung cancer
and metastatic cases [3], the incidence of PB in NSCLC is
regularly less than 1%, a figure comparable to that found in
somewhat broader pathology series [4] which include all
types of lung cancers.
Considering that most patients operated upon for NSCLC
are in their sixties [3], the first striking feature in this
subgroup of tumors is the patients’ young age [5], none
over 46 in the present series. This was already the case in
the first published report on PB [2] and has been corrobo-
rated since in two of the largest published series of PB: the
American military survey [1] and the Danish one [6]. Age
difference is not regularly so obvious [4,7], but this impres-
sion of youth in PB may also have been conveyed by the
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discovery of another variant occurring solely in children and
perhaps misleadingly termed ‘pleuropulmonary blastoma’
[8] (since both diseases are completely different enti-
ties).The latter was reported in 1988 and, unlike the adult
form, only consists of mesenchymal tumor cells; one-fourth
are hereditary [9].
Another curious feature frequently observed in PB is
female prevalence [5,10,11], as in our study where four of
five patients were women. Here again, even when the differ-
ence is not so striking [6,12], gender distribution in PB
never reaches the 5 to 1 male to female ratio regularly
encountered in NSCLC [3]. As for NSCLC, the imbalance
may also result from hormonal status in young women with
high levels of circulating estrogen [13].
PB frequently appear as large and well demarcated
masses [1,4]: Koss et al.’s 24 cases average 10.1 cm in
their largest diameter (up to 27 cm!) [1] – and 6.9 cm in
the Danish series [4] (some consider size a predictive factor
when .5 cm [1]). This bulkiness probably explains why so
many cases of PB are symptomatic [1,9,10]. Our single
asymptomatic patient had his 6 cm-lung tumor discovered
on a yearly routine chest X-ray examination, 2 years after
irradiation of a squamous-cell carcinoma of the anus.
Conversely, NSCLC cases have smaller tumors in general,
and hence are less often symptomatic (exactly one out of
five cases in a local series [3]).
The tumor may be fast growing – as in the case illu-
strated, almost invariably unique [9] and if not, limited to
one lung; bilateral disease is exceptional (one case reported
in 83 [6]). In spite of occasional differences – upper lobe
prevalence in the present series, lower lobes in a pediatric
one [9] – all pulmonary lobes seem equally affected [6].
Despite univocal histologic features making PB resemble
fetal lung at 3–4 months of gestation, preoperative biopsy or
cytology studies [1,14] – occasionally undertaken to warrant
a conservative stand in the face of a long-standing isolated
and reassuring mass (some have been known for 6 years!
[5]) – are frequently unspecific [6,15]. The same holds true
for bronchoscopy which is unable to show and biopsy these
frequently peripheral tumors [16]. According to the Danish
survey, a correct preoperative diagnosis [10] was obtained
in only one-third of cases [6]. One feature, however, which
should arise suspicion for PB is the presence of necrosis, a
finding usually absent in other benign conditions with
misleading radiologic resemblance [1,17]. These include
hamartomas, carcinoid tumors [16], or even solitary fibrous
tumors of the pleura [18], which is all the more frustrating
given the frequently ominous outcome of PB.
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Fig. 1. Chest radiographies of fifth patient in Table 1 demonstrating extremely rapid tumor growth in only 11 days.
Table 2
Cases of pulmonary blastoma compared to all primary lung cancers operated
No. of
cases
Age (mean) Sex (M/F) (%) Patients with
symptoms (%)
Patients with N2
disease (%)
Median survival
(years)
Operated primary lung cancers 1918 27–83 (61) 1559/359 (81/19) 863 (45) 403 (21) 3.7
Pulmonary blastomas 5 32–46 (37) 1/4 4 4 , 1.0
Mediastinal N2 lymph node involvement – stage IIIA
(observed in four of our five cases) would be expected to
be frequent in view of the grim outcome of these tumors.
Curiously, it is quite rare when noted [16]: three instances of
lymph node metastasis in the 24-case American series
(12%) – which may also have been N1 nodes – and three
out of 11 in the Danish one [4]. Also, for some obscure
reason, metastases – be it lymphatic or in another organ –
do not necessarily reproduce the biphasic primary tumor
architecture [4]: patients whose metastases were examined
showed evenly distributed monotype and mixed histologies
[6]; our 33-year old patient had her N2 lymph node
composed solely of glandular cells. All in all, incidence of
N2 disease in PB [9] compares closely with that of N2
disease in operated NSCLC (17% in Geneva, for instance
[3]) and probably explains why N2 involvement per se was
not found sufficiently predictive.
Finally, prognosis of PB is poor, since only one out of six
patients survives $5 years [6], which is worse than for
operated NSCLC considered as a whole. In the Danish
survey of 83 cases – and quite expectedly – patients having
undergone surgery (n ¼ 66) had a mean survival of 33
months, versus only two when they were deemed inoperable
(n ¼ 17) [6]. Surgery should obviously aim to be curative,
even though ‘subtotal’ resections backed by radio- and
chemotherapy have occasionally afforded significant survi-
vals (up to 7 years [17]) [16]. Interestingly, the situation is
not quite so grim for children with pleuropulmonary blas-
toma (quite a different entity, as mentioned earlier), despite
higher numbers of inoperable tumors [9], since survival
averages 30% at 5 years. Recurrences and metastases,
observed in two-thirds of adult patients in the Danish series,
and precocious in another one [1] are predominantly thor-
acic, occurring twice as often in N2 nodes than in remaining
lung tissue (after surgery).
In conclusion, when compared to NSCLC, PB are rare,
larger, and symptomatic tumors; they affect younger patients
and carry a worse prognosis. PB are all the more treacherous
since imaging may mimic other benign conditions. Without
resorting to undue work-up which is still inconclusive in two-
thirds of cases, surgical excision should thus be rapidly
contemplated for such large solitary pulmonary masses.
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